Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LYPLAL1 antisense RNA 1 (LYPLAL1-AS1)
- Target
- LYPLAL1-AS1
- Molecular classification
- Long noncoding RNA [lncRNA], Antisense RNA
01
Overview
LYPLAL1 antisense RNA 1 (LYPLAL1-AS1) is a long noncoding RNA (lncRNA) transcribed antisense to the LYPLAL1 gene on chromosome 1 and is 523 nucleotides in length. It is primarily cytoplasmic in human adipose-derived mesenchymal stem cells and is strongly upregulated during adipogenic differentiation. LYPLAL1-AS1 regulates this process by targeting the protein desmoplakin, modulating its stability (likely via the proteasome), resulting in inhibition of the Wnt/β-catenin signaling pathway, and promoting adipocyte lineage commitment. Its activity suggests an important role in adipogenesis and potential as a therapeutic target for obesity and related metabolic disorders, though there are currently no direct therapeutic agents targeting this RNA. The predominance in the cytoplasm and specific upregulation during adipogenesis underscore its functional significance in fat cell development
- Other names
- LYPLAL1-AS1LYPLAL1 antisense RNA 1
02
Mechanism of action
No direct drugs, but manipulation (e.g., knockdown or overexpression) of LYPLAL1-AS1 alters adipogenic differentiation through modulation of desmoplakin protein stability and inhibition of the Wnt/β-catenin pathway
03
Biological functions
Regulation of adipogenic differentiationModulation of mesenchymal stem cell lineage fatePost-transcriptional regulation of protein stability (notably desmoplakin)Inhibition of Wnt/β-catenin signaling pathway
04
Disease associations
ObesityAdipogenesis-related disordersPotentially other disorders related to abnormal fat cell development
05
Safety considerations
Targeting lncRNAs may present delivery and specificity challenges due to their nuclear/cytoplasmic localization and poor sequence conservation across speciesOff-target effects on vital differentiation pathways in stem cells should be considered
06
Biomarkers
LYPLAL1-AS1 expression may serve as a biomarker for adipogenic differentiation potential or abnormal adipogenesis
Beyond the preview
Go deeper on LYPLAL1 antisense RNA 1 (LYPLAL1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYPLAL1 antisense RNA 1 (LYPLAL1-AS1).